Suzanne Lentzsch
0000-0003-1708-7344
Publication & Citation Trends
Publications
0 total
Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma OA
Cited by 9
Semantic Scholar
Absence of Stat1 in donor CD4+ T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice. OA
Cited by 1
Semantic Scholar
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study OA
Cited by 64
Semantic Scholar
The clinical trials landscape in immunoglobulin light chain amyloidosis: a systematic review OA
Cited by 1
Semantic Scholar
Efficacy and safety of 40 mg vs 60 mg once weekly selinexor in combination with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma (RRMM).
Cited by 1
Semantic Scholar
Reduced Early Mortality with Daratumumab-Based Frontline Therapy in Systemic AL Amyloidosis- Experience from the Columbia Amyloidosis Multidisciplinary Program OA
Cited by 2
Semantic Scholar
LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma.
Cited by 48
Semantic Scholar
Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study OA
Cited by 16
Semantic Scholar
Research Topics
Multiple Myeloma Research and Treatments
(329)
Protein Degradation and Inhibitors
(112)
Amyloidosis: Diagnosis, Treatment, Outcomes
(111)
Peptidase Inhibition and Analysis
(59)
Chronic Lymphocytic Leukemia Research
(48)
Affiliations
Rutgers, The State University of New Jersey
University of Leeds
NewYork–Presbyterian Hospital
Harvard University
University of Pittsburgh